ABSIAbsci Corp
Services-Commercial Physical & Biological Research
- Revenue
- $3M
- 38% YoY
- Operating margin
- -4297.0%
- 79% YoY
- EBITDA
- −$109M
- 14% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$104M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired654% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $4M | $5M | $6M | $5M | $3M | 38% |
| Operating income | −$75M | −$107M | −$116M | −$109M | −$120M | 10% |
| Net income | −$101M | −$105M | −$111M | −$103M | −$115M | 12% |
| Operating cash flow | −$61M | −$81M | −$65M | −$72M | −$93M | 28% |
| Capex | $38M | $16M | $860K | $404K | $1M | 174% |
| Stock-based comp | $11M | $13M | $11M | $19M | $18M | 5.8% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.